Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.

Publication ,  Journal Article
Overman, MJ; Kazmi, SM; Jhamb, J; Lin, E; Yao, JC; Abbruzzese, JL; Ho, L; Ajani, J; Phan, A
Published in: Cancer
March 15, 2010

BACKGROUND: Docetaxel, cisplatin, and 5-flurouracil (DCF) administered every 3 weeks produces a high rate of treatment-related adverse events. The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF. METHODS: Data from 117 patients treated at The University of Texas M. D. Anderson Cancer Center from 2002 to 2006 with a weekly formulation of DCF were retrospectively collected. A total of 95 patients received front-line therapy with 20 mg/m(2) of cisplatin, 350 mg/m(2) of 5-fluorouracil, and 20 mg/m(2) of docetaxel administered once weekly for 6 consecutive weeks followed by a 2-week break. RESULTS: Ninety-five patients (median age, 62 years [range, 33 to 87 years], with an Eastern Cooperative Oncology Group performance status of 1 or 2 in 67%) received a median of 10 weeks of DCF treatment (range, 3-41 weeks). Grade 3 or 4 hematologic toxicity (assessed according to National Cancer Institute Common Toxicity Criteria [version 3.0]) included granulocytopenia (4 patients) and anemia (9 patients). None of the patients developed a febrile neutropenic infection, but grade 3 or 4 non-neutropenic infections occurred in 8 patients. Eighty patients had measurable disease with an objective response rate determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria of 34% (95% confidence interval [95% CI], 24-45%). The median follow-up was 9 months, with a median time to disease progression of 4.1 months (95% CI, 3.6-5.7 months) and a median overall survival of 8.9 months (95% CI, 7.7-10.8 months). CONCLUSIONS: In patients with advanced gastric and esophageal cancer who were not candidates for every-3-week DCF, a weekly formulation of DCF demonstrated modest activity with minimal hematologic toxicity, suggesting that weekly DCF is a reasonable treatment option for such patients.

Duke Scholars

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

March 15, 2010

Volume

116

Issue

6

Start / End Page

1446 / 1453

Location

United States

Related Subject Headings

  • Taxoids
  • Stomach Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Esophageal Neoplasms
  • Drug Administration Schedule
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Overman, M. J., Kazmi, S. M., Jhamb, J., Lin, E., Yao, J. C., Abbruzzese, J. L., … Phan, A. (2010). Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer, 116(6), 1446–1453. https://doi.org/10.1002/cncr.24925
Overman, Michael J., Syed M. Kazmi, Jagriti Jhamb, E. Lin, James C. Yao, James L. Abbruzzese, Linus Ho, Jaffer Ajani, and Alexandria Phan. “Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.Cancer 116, no. 6 (March 15, 2010): 1446–53. https://doi.org/10.1002/cncr.24925.
Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15;116(6):1446–53.
Overman, Michael J., et al. “Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.Cancer, vol. 116, no. 6, Mar. 2010, pp. 1446–53. Pubmed, doi:10.1002/cncr.24925.
Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15;116(6):1446–1453.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

March 15, 2010

Volume

116

Issue

6

Start / End Page

1446 / 1453

Location

United States

Related Subject Headings

  • Taxoids
  • Stomach Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Esophageal Neoplasms
  • Drug Administration Schedule